Takata Takanobu, Inoue Shinya, Kunii Kenshiro, Masauji Togen, Moriya Junji, Motoo Yoshiharu, Miyazawa Katsuhito
Division of Molecular and Genetic Biology, Department of Life Science, Medical Research Institute, Kanazawa Medical University, Uchinada 920-0293, Ishikawa, Japan.
Department of Pharmacy, Kanazawa Medical University Hospital, Uchinada 920-0293, Ishikawa, Japan.
Diseases. 2025 Jan 2;13(1):7. doi: 10.3390/diseases13010007.
Urinary stones (urolithiasis) have been categorized as kidney stones (renal calculus), ureteric stones (ureteral calculus and ureterolith), bladder stones (bladder calculus), and urethral stones (urethral calculus); however, the mechanisms underlying their promotion and related injuries in glomerular and tubular cells remain unclear. Although lifestyle-related diseases (LSRDs) such as hyperglycemia, type 2 diabetic mellitus, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, and cardiovascular disease are risk factors for urolithiasis, the underlying mechanisms remain unclear. Recently, heat shock protein 90 (HSP90) on the membrane of HK-2 human proximal tubular epithelium cells has been associated with the adhesion of urinary stones and cytotoxicity. Further, HSP90 in human pancreatic and breast cells can be modified by various advanced glycation end-products (AGEs), thus affecting their function. Hypothesis 1: We hypothesized that HSP90s on/in human proximal tubular epithelium cells can be modified by various types of AGEs, and that they may affect their functions and it may be a key to reveal that LSRDs are associated with urolithiasis. Hypothesis 2: We considered the possibility that Japanese traditional medicines for urolithiasis may inhibit AGE generation. Of Choreito and Urocalun (the extract of Blume/ Makino) used in the clinic, Choreito is a Kampo medicine, while Urocalun is a characteristic Japanese traditional medicine. As Urocalun contains quercetin, hesperidin, and -hydroxy cinnamic acid, which can inhibit AGE generation, we hypothesized that Urocalun may inhibit the generation of AGE-modified HSP90s in human proximal tubular epithelium cells.
尿路结石(尿石症)已被分类为肾结石(肾石)、输尿管结石(输尿管结石和输尿管石)、膀胱结石(膀胱结石)和尿道结石(尿道结石);然而,其在肾小球和肾小管细胞中的促进机制及相关损伤仍不清楚。尽管高血糖、2型糖尿病、非酒精性脂肪性肝病/非酒精性脂肪性肝炎和心血管疾病等生活方式相关疾病(LSRDs)是尿石症的危险因素,但其潜在机制仍不清楚。最近,人近端肾小管上皮细胞HK-2膜上的热休克蛋白90(HSP90)与尿路结石的黏附及细胞毒性有关。此外,人胰腺和乳腺细胞中的HSP90可被多种晚期糖基化终产物(AGEs)修饰,从而影响其功能。假设1:我们假设人近端肾小管上皮细胞上/内的HSP90可被多种类型的AGEs修饰,且它们可能影响其功能,这可能是揭示LSRDs与尿石症相关的关键。假设2:我们考虑了用于治疗尿石症的日本传统药物可能抑制AGE生成的可能性。在临床使用的消石利胆汤和优克龙(Blume/Makino提取物)中,消石利胆汤是一种汉方药物,而优克龙是一种典型的日本传统药物。由于优克龙含有可抑制AGE生成的槲皮素、橙皮苷和对羟基肉桂酸,我们假设优克龙可能抑制人近端肾小管上皮细胞中AGE修饰的HSP90的生成。